アルファ放出核種市場：放射性核種タイプ別、用途別-2025-2030年の世界予測

アルファ放出核種市場は、2023年に8億8,695万米ドルと評価され、2024年には10億6,244万米ドルに達すると予測され、CAGR 20.18%で成長し、2030年には32億1,195万米ドルに達すると予測されています。

アルファ放出核種は、アルファ粒子を放出する放射性医薬品のカテゴリーであり、周囲の健康な組織への影響を最小限に抑えながら腫瘍に高濃度の線量を供給できることから、主に特定のがんの治療に使用されています。がんが世界の健康上の重要課題であり続ける中、がんの有病率の増加、核医学の進歩、個別化医療への移行を背景に、アルファ放出核種の市場は必要な拡大を見せています。特に、これらのエミッターは多発性骨髄腫、非ホジキンリンパ腫、前立腺がんの治療に応用されており、最終用途分野は病院、がん治療センター、研究機関に及んでいます。市場は、ヘルスケア支出の増加、技術の進歩、がん治療に対する政府の取り組みの増加といった要因の影響を受けています。しかし、先進的ながん治療に対するニーズが急増していることや、規制の枠組みが整備されていることから、新興市場にも潜在的なビジネスチャンスが存在しています。企業がこうした機会を生かすには、アルファ線を放出する新薬の研究開発への投資やヘルスケア機関との提携が極めて重要となります。こうしたビジネスチャンスがある一方で、市場は厳しい規制要件、生産・研究コストの高さ、特に新興国地域における認知度や入手のしにくさといった制約に直面しています。また、放射性物質を安全に取り扱うための専門的なインフラや熟練した人材の必要性といった課題もあります。これらのハードルを克服するために、企業はアルファ放出核種の治療指数を高めるためのより効果的な送達システムの開拓、アイソトープ生産技術の改善、試験と市場参入を迅速化するためのバイオテクノロジー企業とのパートナーシップの促進などのイノベーションに注力すべきです。市場競争は激しく進化しており、革新的な治療手法への取り組みと適用範囲の拡大により、将来の展望は可能性に満ちています。

市場力学：急速に進化するアルファ放出核種市場の主要市場インサイトを公開

アルファ放出核種市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心疾患およびがん患者の増加
  • 標的アルファ線放出装置の潜在的利益に対する認識の高まり
  • 産業分野におけるアルファ放出核種の新たな利用
• 市場抑制要因
  • アルファ放出核種の製造コストの高さ
• 市場機会
  • がん治療のための新たな臨床試験活動の開始
  • アルファ放出核種の新たな応用分野を開拓するための継続的な研究開発活動
• 市場の課題
  • アルファ放出核種の複雑な取り扱いと安全上の危険性

ポーターの5つの力：アルファ放出核種市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、アルファ放出核種市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アルファ放出核種市場における外部からの影響の把握

外部マクロ環境要因は、アルファ放出核種市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アルファ放出核種市場における競合情勢の把握

アルファ放出核種市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアルファ放出核種市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アルファ放出核種市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アルファ放出核種市場における成功への道筋を描く

アルファ放出核種市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心臓病やがんの患者数の増加
    • 標的アルファ線放射体の潜在的利点に対する認識の高まり
    • 産業分野におけるアルファ放出核種の新たな利用
  • 抑制要因
    • アルファ放出核種の生産コストが高い
  • 機会
    • がん治療のための新たな臨床試験活動の出現
    • アルファ放出核種の新たな応用分野を開拓するための継続的な研究開発活動
  • 課題
    • アルファ放出核種の複雑な取り扱いと安全上の危険性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アルファ放出核種市場放射性核種の種類別

• アクチニウム225
• アメリシウム241
• アスタチン-211
• プルトニウム239
• ラジウム226
• ウラン238

第7章 アルファ放出核種市場：用途別

• 産業
• 医学
  • 骨転移
  • 内分泌腫瘍
  • 卵巣がん
  • 膵臓がん
  • 前立腺がん

第8章 南北アメリカのアルファ放出核種市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のアルファ放出核種市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのアルファ放出核種市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Actinium Pharmaceuticals, Inc.
• Alpha Tau Medical Ltd.
• Bayer AG
• Bracco S.p.A.
• Cardinal Health, Inc.
• Eckert & Ziegler
• Fusion Pharmaceuticals Inc.
• Ionetix Corporation
• Niowave Inc.
• Orano Group
• RadioMedix, Inc.
• Siemens Healthineers
• Telix Pharmaceuticals Limited

LIST OF FIGURES

• FIGURE 1. ALPHA EMITTERS MARKET RESEARCH PROCESS
• FIGURE 2. ALPHA EMITTERS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ALPHA EMITTERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ALPHA EMITTERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ALPHA EMITTERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ALPHA EMITTERS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ALPHA EMITTERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ALPHA EMITTERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ALPHA EMITTERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ALPHA EMITTERS MARKET DYNAMICS
• TABLE 7. GLOBAL ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ALPHA EMITTERS MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ALPHA EMITTERS MARKET SIZE, BY AMERICIUM-241, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ALPHA EMITTERS MARKET SIZE, BY ASTATINE-211, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ALPHA EMITTERS MARKET SIZE, BY PLUTONIUM-239, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ALPHA EMITTERS MARKET SIZE, BY RADIUM-226, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ALPHA EMITTERS MARKET SIZE, BY URANIUM-238, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ALPHA EMITTERS MARKET SIZE, BY MEDICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ALPHA EMITTERS MARKET SIZE, BY BONE METASTASIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ALPHA EMITTERS MARKET SIZE, BY ENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ALPHA EMITTERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ALPHA EMITTERS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ALPHA EMITTERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 33. CANADA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. CANADA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES ALPHA EMITTERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 50. CHINA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. CHINA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 53. INDIA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDIA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 105. ITALY ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. ITALY ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 117. POLAND ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. POLAND ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 120. QATAR ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. QATAR ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM ALPHA EMITTERS MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM ALPHA EMITTERS MARKET SIZE, BY MEDICAL, 2018-2030 (USD MILLION)
• TABLE 150. ALPHA EMITTERS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. ALPHA EMITTERS MARKET, FPNV POSITIONING MATRIX, 2023

The Alpha Emitters Market was valued at USD 886.95 million in 2023, expected to reach USD 1,062.44 million in 2024, and is projected to grow at a CAGR of 20.18%, to USD 3,211.95 million by 2030.

Alpha emitters are a category of radiopharmaceuticals that release alpha particles, primarily used in the treatment of certain cancers due to their ability to deliver highly concentrated doses to tumors with minimal impact on surrounding healthy tissues. As cancer continues to be a significant global health challenge, the market for alpha emitters is seeing a necessary expansion, driven by the increasing prevalence of cancer, advancements in nuclear medicine, and the transition towards personalized medicine. Notably, these emitters are being applied in the treatment of multiple myeloma, non-Hodgkin's lymphoma, and prostate cancer, with end-use sectors spanning hospitals, cancer treatment centers, and research institutes. The market is influenced by factors such as rising healthcare spending, technological advancement, and increased government initiatives for cancer treatment. However, potential opportunities exist in emerging markets due to the burgeoning need for advanced cancer treatments and supportive regulatory frameworks. For companies to capitalize on these opportunities, investments in R&D for new alpha-emitting drugs and collaborations with healthcare institutions can be pivotal. Despite these opportunities, the market faces limitations such as stringent regulatory requirements, high costs of production and research, and limited awareness and accessibility, especially in developing regions. Challenges also include the need for specialized infrastructure and skilled personnel to handle these radioactive substances safely. To overcome these hurdles, companies should focus on innovations, such as developing more effective delivery systems to enhance the therapeutic index of alpha emitters, improving isotopic production technologies, and fostering partnerships with biotechnology firms to expedite trials and market entry. The market is highly competitive and evolving, with a push towards innovative treatment methodologies and expanding applicability scopes promising a future vibrant with possibilities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alpha Emitters Market

The Alpha Emitters Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing number of patients with cardiac and cancer ailments
  • Increased awareness of potential benefits of targeted alpha emitter
  • Emerging use of alpha emitters in industrial sectors
• Market Restraints
  • High cost of production of alpha emitters
• Market Opportunities
  • Emerging new clinical trial activities for cancer treatment
  • Ongoing R&D activities for exploring new application areas of alpha emitters
• Market Challenges
  • Complex handling and safety hazards of alpha emitters

Porter's Five Forces: A Strategic Tool for Navigating the Alpha Emitters Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alpha Emitters Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alpha Emitters Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alpha Emitters Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alpha Emitters Market

A detailed market share analysis in the Alpha Emitters Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alpha Emitters Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alpha Emitters Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alpha Emitters Market

A strategic analysis of the Alpha Emitters Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alpha Emitters Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Alpha Tau Medical Ltd., Bayer AG, Bracco S.p.A., Cardinal Health, Inc., Eckert & Ziegler, Fusion Pharmaceuticals Inc., Ionetix Corporation, Niowave Inc., Orano Group, RadioMedix, Inc., Siemens Healthineers, and Telix Pharmaceuticals Limited.

Market Segmentation & Coverage

This research report categorizes the Alpha Emitters Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Radionuclide Type, market is studied across Actinium-225, Americium-241, Astatine-211, Plutonium-239, Radium-226, and Uranium-238.
• Based on Application, market is studied across Industrial and Medical. The Medical is further studied across Bone Metastasis, Endocrine Tumors, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing number of patients with cardiac and cancer ailments
    • 5.1.1.2. Increased awareness of potential benefits of targeted alpha emitter
    • 5.1.1.3. Emerging use of alpha emitters in industrial sectors
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of production of alpha emitters
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging new clinical trial activities for cancer treatment
    • 5.1.3.2. Ongoing R&D activities for exploring new application areas of alpha emitters
  • 5.1.4. Challenges
    • 5.1.4.1. Complex handling and safety hazards of alpha emitters
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Alpha Emitters Market, by Radionuclide Type

• 6.1. Introduction
• 6.2. Actinium-225
• 6.3. Americium-241
• 6.4. Astatine-211
• 6.5. Plutonium-239
• 6.6. Radium-226
• 6.7. Uranium-238

7. Alpha Emitters Market, by Application

• 7.1. Introduction
• 7.2. Industrial
• 7.3. Medical
  • 7.3.1. Bone Metastasis
  • 7.3.2. Endocrine Tumors
  • 7.3.3. Ovarian Cancer
  • 7.3.4. Pancreatic Cancer
  • 7.3.5. Prostate Cancer

8. Americas Alpha Emitters Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Alpha Emitters Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Alpha Emitters Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Actinium Pharmaceuticals, Inc.
• 2. Alpha Tau Medical Ltd.
• 3. Bayer AG
• 4. Bracco S.p.A.
• 5. Cardinal Health, Inc.
• 6. Eckert & Ziegler
• 7. Fusion Pharmaceuticals Inc.
• 8. Ionetix Corporation
• 9. Niowave Inc.
• 10. Orano Group
• 11. RadioMedix, Inc.
• 12. Siemens Healthineers
• 13. Telix Pharmaceuticals Limited